Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523698717> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2523698717 abstract "Laquinimod is an orally available quinoline 3-carboxamide derivative drug studied in phase II and III clinical trials for relapsing-remitting multiple sclerosis (RRMS), systemic lupus erythematosus, and Crohn disease. Laquinimod has shown promise in RRMS clinical trials,1,2 and identifying the mechanism underlying its disease-modifying effects could help target it to the patient population where it would be most effective. Studies in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis (MS) have suggested that the drug may ameliorate disease by modulating innate and adaptive immune responses, for example via effects on macrophages/monocytes, dendritic cells (DCs), and T-helper (Th) cells.3–5 However, its key effector mechanisms and the cellular targets by which the drug ameliorates disease are still not fully resolved. The article by Varrin-Doyer et al.6 in this issue of Neurology ® Neuroimmunology & Neuroinflammation sheds new light on this question and provides important insights that could be relevant for the treatment of MS. In elegant experiments, Varrin-Doyer et al. provide convincing evidence that treatment with laquinimod strongly ameliorates disease in 2 models of recombinant myelin oligodendrocyte glycoprotein (MOG)–induced EAE and spontaneous EAE in mice transgenic for a T-cell receptor specific for MOG35-55 peptide and a MOG-specific immunoglobulin H chain knock-in (2D2 × Th mice). In both of these models, the authors show that laquinimod treatment prevented the development of T-follicular-helper (Tfh) cells and decreased the production of MOG-specific immunoglobulin G antibodies. Interestingly, in a spontaneous model of EAE, associated with the formation of meningeal follicle-like structures that are populated by B and T cells,7 laquinimod therapy reduced the number and the size of these cellular aggregates." @default.
- W2523698717 created "2016-09-30" @default.
- W2523698717 creator A5008482088 @default.
- W2523698717 creator A5035339589 @default.
- W2523698717 date "2016-09-21" @default.
- W2523698717 modified "2023-09-27" @default.
- W2523698717 title "Targeting “bad” B cells in multiple sclerosis" @default.
- W2523698717 cites W1978631279 @default.
- W2523698717 cites W1985038762 @default.
- W2523698717 cites W2011324376 @default.
- W2523698717 cites W2015847142 @default.
- W2523698717 cites W2086620596 @default.
- W2523698717 cites W2105167551 @default.
- W2523698717 cites W2108193014 @default.
- W2523698717 cites W2122397885 @default.
- W2523698717 cites W2141111992 @default.
- W2523698717 cites W2522200429 @default.
- W2523698717 doi "https://doi.org/10.1212/nxi.0000000000000283" @default.
- W2523698717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5032664" @default.
- W2523698717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27704037" @default.
- W2523698717 hasPublicationYear "2016" @default.
- W2523698717 type Work @default.
- W2523698717 sameAs 2523698717 @default.
- W2523698717 citedByCount "0" @default.
- W2523698717 crossrefType "journal-article" @default.
- W2523698717 hasAuthorship W2523698717A5008482088 @default.
- W2523698717 hasAuthorship W2523698717A5035339589 @default.
- W2523698717 hasBestOaLocation W25236987171 @default.
- W2523698717 hasConcept C203014093 @default.
- W2523698717 hasConcept C2776914184 @default.
- W2523698717 hasConcept C2778486448 @default.
- W2523698717 hasConcept C2779357208 @default.
- W2523698717 hasConcept C2780640218 @default.
- W2523698717 hasConcept C71924100 @default.
- W2523698717 hasConcept C87753298 @default.
- W2523698717 hasConcept C8891405 @default.
- W2523698717 hasConceptScore W2523698717C203014093 @default.
- W2523698717 hasConceptScore W2523698717C2776914184 @default.
- W2523698717 hasConceptScore W2523698717C2778486448 @default.
- W2523698717 hasConceptScore W2523698717C2779357208 @default.
- W2523698717 hasConceptScore W2523698717C2780640218 @default.
- W2523698717 hasConceptScore W2523698717C71924100 @default.
- W2523698717 hasConceptScore W2523698717C87753298 @default.
- W2523698717 hasConceptScore W2523698717C8891405 @default.
- W2523698717 hasLocation W25236987171 @default.
- W2523698717 hasLocation W25236987172 @default.
- W2523698717 hasLocation W25236987173 @default.
- W2523698717 hasLocation W25236987174 @default.
- W2523698717 hasOpenAccess W2523698717 @default.
- W2523698717 hasPrimaryLocation W25236987171 @default.
- W2523698717 hasRelatedWork W1523338791 @default.
- W2523698717 hasRelatedWork W1978007980 @default.
- W2523698717 hasRelatedWork W2001642942 @default.
- W2523698717 hasRelatedWork W2013932229 @default.
- W2523698717 hasRelatedWork W2018560721 @default.
- W2523698717 hasRelatedWork W2019028932 @default.
- W2523698717 hasRelatedWork W2037580394 @default.
- W2523698717 hasRelatedWork W2051543984 @default.
- W2523698717 hasRelatedWork W207868984 @default.
- W2523698717 hasRelatedWork W2079899001 @default.
- W2523698717 hasRelatedWork W2087580038 @default.
- W2523698717 hasRelatedWork W2096908144 @default.
- W2523698717 hasRelatedWork W2108068190 @default.
- W2523698717 hasRelatedWork W2121284143 @default.
- W2523698717 hasRelatedWork W2178419939 @default.
- W2523698717 hasRelatedWork W2329693846 @default.
- W2523698717 hasRelatedWork W2398591771 @default.
- W2523698717 hasRelatedWork W2415756143 @default.
- W2523698717 hasRelatedWork W2527211602 @default.
- W2523698717 hasRelatedWork W3167349706 @default.
- W2523698717 isParatext "false" @default.
- W2523698717 isRetracted "false" @default.
- W2523698717 magId "2523698717" @default.
- W2523698717 workType "article" @default.